

portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific

4) a second targetable conjugate which comprises a carrier

10

3) a prodrug which is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site,

2) a drug which is capable of being detoxified in said patient to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the

h admistering to said patient

(D) when said targetable conjugate comprises an enzyme, further

or enzymes; and

antibody fragment, and one or more conjugated therapeutic or diagnostic agents;

recogmizable by said at least one other arm of said bi-specific antibody or

comprises a carrier portion which comprises or bears at least one epitope

(C) administering to said patient a first targetable conjugate which

### fragments from circulation;

(B) optionally, administering to said patient a clearing composition, and allowing said composition to clear non-localized antibodies or antibody

(A) administering to said patient a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;

A method of dealing with identical disease issues in a patient.

## WHAT IS CLAIMED IS:

ପାତା ୧୦୦

antibody or antibody fragment, and a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site.

2. The method of claim 1, further comprising, when said first targetable conjugate comprises a prodrug, administering a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and an enzyme capable of converting said prodrug to a drug or of reconverting a detoxified intermediate of said drug to a toxic form.
3. The method of claim 1, wherein said targetable conjugate comprises one or more radioactive isotopes useful for killing diseased tissue.
4. The method of claim 1, wherein said targetable conjugate comprises boron atoms, and said method further comprises the step of irradiating said boron atoms localized at said diseased tissue, thereby effecting BNCT of said diseased tissue.
5. The method of claim 1, wherein said targetable conjugate comprises one or more toxins.
6. The method of claim 1, wherein said targetable conjugate comprises one or more drugs.
7. The method of claim 1, wherein said targetable conjugate comprises one or more prodrugs.
8. The method of claim 1, wherein said targetable conjugate comprises one or more radioactive isotopes useful for detecting diseased tissue.

9. The method of claim 1, wherein said targetable conjugate comprises one or more image enhancing agents for use in magnetic resonance imaging (MRI).

10. The method of claim 1, wherein said at least one arm that specifically binds a targeted tissue is a monoclonal antibody or a fragment of a monoclonal antibody.

11. The method of claim 1, wherein said at least one other arm that specifically binds a targetable conjugate is a monoclonal antibody or a fragment of a monoclonal antibody.

12. The method of claim 1, wherein said at least one arm that specifically binds a targeted tissue is a humanized antibody or a fragment of a humanized antibody.

13. The method of claim 1, wherein said at least one other arm that specifically binds a targetable conjugate is a humanized antibody or a fragment of a humanized antibody.

14. The method of claim 1, wherein said targetable conjugate comprises a peptide.

15. The method of claim 1, wherein said targetable conjugate comprises a carbohydrate.

16. The method of claim 1, wherein said targetable conjugate comprises one or more haptens.

17. The method of claim 1, wherein said targetable conjugate comprises one or more chelators or metal-chelate complexes.

18. The method of claim 1, wherein said bi-specific antibody or antibody fragment further comprises a radionuclide.

19. The method of claim 17, wherein at least one of said chelators is a hard base chelator for a hard acid cation, and at least one of said chelators is a soft base chelator for a soft acid cation.

20. The method of claim 17, wherein said chelator is a hard base chelator that comprises carboxylate and amine groups.

21. The method of claim 20, wherein said hard base chelator is DTPA, NOTA, DOTA or TETA.

22. The method of claim 17, wherein said targetable conjugate comprises a tyrosyl-lysine dipeptide.

23. The method of claim 22, wherein said targetable conjugate comprises Tyr-Lys(DTPA)-NH<sub>2</sub>, or Lys(DTPA)-Tyr-Lys(DTPA)-NH<sub>2</sub>.

24. The method of claim 23, wherein said targetable conjugate comprises doxorubicin.

25. A kit useful for treating or identifying diseased tissues in a patient comprising:

- (A) a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;
- (B) a first targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and one or more conjugated therapeutic or diagnostic agents, or enzymes; and
- (C) optionally, a clearing composition useful for clearing non-localized antibodies and antibody fragments; and

(D) optionally, when said first targetable conjugate comprises an enzyme,

- 1) a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site; or
- 2) a drug which is capable of being detoxified in said patient to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or
- 3) a prodrug which is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or
- 4) a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and a prodrug, when said enzyme is capable of converting said prodrug to a drug at the target site.

26. A bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate.

27. The bi-specific antibody or antibody fragment of claim 26, wherein said antibody or antibody fragment is humanized.

28. The bi-specific antibody or antibody fragment of claim 26, wherein said antibody or antibody fragment is monoclonal..

29. The method of claim 1, wherein said at least one other arm that specifically binds a targetable conjugate binds a tyrosyl-lysine dipeptide.

30. A recombinant DNA construct comprising an expression cassette capable of producing in a host cell a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding said bi-specific antibody or antibody fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said bi-specific antibody or antibody fragment is under the control of said regulatory regions.

~~31~~ A set of expression cassettes capable of producing a bi-specific antibody or antibody fragment having at least one arm that specifically binds to a targeted tissue and at least one other arm that specifically binds to a targetable conjugate, wherein each cassette comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in a host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a fragment of said bi-specific antibody, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said fragment is under the control of said regulatory regions.

32. A method of preparing a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate, comprising:

- (A) introducing the recombinant DNA construct of claim ~~31~~ into a host cell;
- (B) growing said cell and isolating said antibody or antibody fragment.

33. A method of preparing a bi-specific fusion protein having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate, comprising:

- (1) (A) introducing into a host cell a recombinant DNA construct comprising an expression cassette capable of producing in said host cell a fragment of said bi-specific fusion protein, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a scFv linked to a Fd fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said fragment of said bi-specific fusion protein is under the control of said regulatory regions;
- (B) co-introducing into said host cell a recombinant DNA construct comprising an expression cassette capable of producing in said host cell a light-chain antibody fragment which is complementary to said Fd fragment in (A) and which when associated with said Fd fragment forms a Fab fragment whose binding site is specific for said targeted tissue, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a light-chain antibody fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said light-chain antibody fragment is under the control of said regulatory regions;
- (C) growing said cell and isolating said bi-specific fusion protein, or

- (2) (A) introducing into a first host cell a recombinant DNA construct comprising an expression cassette capable of producing in said first host cell a fragment of said bi-specific fusion protein,

wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said first host cell, a translational initiation regulatory region functional in said first host cell, a DNA sequence encoding a scFv linked to a Fd fragment, and a transcriptional and translational termination regulatory region functional in said first host cell, wherein said fragment of said bi-specific fusion protein is under the control of said regulatory regions;

(B) introducing into a second host cell a recombinant DNA construct comprising an expression cassette capable of producing in said second host cell a light-chain antibody fragment which is complementary to said Fd fragment in (2)(A) and which when associated with said Fd fragment forms a Fab fragment whose binding site is specific for said targeted tissue, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said second host cell, a translational initiation regulatory region functional in said second host cell, a DNA sequence encoding a light-chain antibody fragment, and a transcriptional and translational termination regulatory region functional in said second host cell, wherein said light-chain antibody fragment is under the control of said regulatory regions;

(C) growing said first and second host cells;

(D) optionally isolating said bi-specific fusion protein fragment and said light-chain antibody fragment; and

(E) combining said fragments to produce a bi-specific fusion protein and isolating said bi-specific fusion protein.

34. A method of preparing a bi-specific fusion protein having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate, comprising:

(1) (A) introducing into a host cell a recombinant DNA construct

comprising an expression cassette capable of producing in said host cell a fragment of said bi-specific fusion protein, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a scFv linked to a light-chain antibody fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said fragment of said bi-specific fusion protein is under the control of said regulatory regions;

(B) co-introducing into said host cell a recombinant DNA construct comprising an expression cassette capable of producing in said host cell a Fd fragment which is complementary to said light-chain antibody fragment in (A) and which when associated with said light-chain antibody fragment forms a Fab fragment whose binding site is specific for said targeted tissue, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said host cell, a translational initiation regulatory region functional in said host cell, a DNA sequence encoding a Fd fragment, and a transcriptional and translational termination regulatory region functional in said host cell, wherein said Fd fragment is under the control of said regulatory regions;

(C) growing said cell and isolating said bi-specific fusion protein, or

(2) (A) introducing into a first host cell a recombinant DNA construct comprising an expression cassette capable of producing in said first host cell a fragment of said bi-specific fusion protein, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said first host cell, a translational initiation regulatory region functional in said first host cell, a DNA sequence encoding a scFv linked to a light-chain antibody

fragment, and a transcriptional and translational termination regulatory region functional in said first host cell, wherein said fragment of said bi-specific fusion protein is under the control of said regulatory regions;

(B) introducing into a second host cell a recombinant DNA construct comprising an expression cassette capable of producing in said second host cell a Fd fragment which is complementary to said light-chain antibody fragment in (2)(A) and which when associated with said light-chain antibody fragment forms a Fab fragment whose binding site is specific for said targeted tissue, wherein said construct comprises, in the 5' to 3' direction of transcription, a transcriptional initiation regulatory region functional in said second host cell, a translational initiation regulatory region functional in said second host cell, a DNA sequence encoding a Fd fragment, and a transcriptional and translational termination regulatory region functional in said second host cell, wherein said Fd fragment is under the control of said regulatory regions;

(C) growing said first and second host cells;

(D) optionally isolating said bi-specific fusion protein fragment and said Fd fragment; and

(E) combining said fragments to produce a bi-specific fusion protein and isolating said bi-specific fusion protein.